NTT Electronics starts shipping 140 Gbaud High-performance Coherent DSP
6.3.2023 21:00:00 EET | Business Wire | Press release
NTT Electronics, a leading supplier of coherent Digital Signal Processor (DSP) solutions to system and module manufacturers worldwide, today announced start of 140 Gbaud high-performance coherent DSP (ExaSPEED GAIA) shipment to customers. ExaSPEED GAIA achieves world's largest transmission capacity of 1.2 Tbit/s per wavelength by utilizing a programmable baud rate of up to 140 Gbaud powered by a flexible coded modulation scheme and advanced 5nm FinFET CMOS process.
“We are excited to add the ExaSPEED GAIA DSP to our product portfolio which cuts the power consumption per bit to half while doubling the baud rate over earlier product offering,” said Satoshi Shigematsu, NTT Electronics General Manager of Broadband System & Device Business Unit. “We believe this high-performance DSP will help our customers offer highly differentiated optical transmission equipment and systems”, he added.
The programmable baud rate can support very fine granularity that enables ExaSPEED GAIA to adapt to a range of links while maximizing spectral efficiency. These include short-reach data center interconnects (DCI), terrestrial metro links with cascaded ROADMs, and ultra-long-haul sub-sea links. Customers can use a wide range of 400G interfaces in 1.2T (3x400GbE) for DCI, 800G (2x400GbE) for metro and 400G (1x400GbE) for sub-sea applications. This capability helps simplify interfaces and optimize Capital/Operational expenditure. Moreover, ExaSPEED GAIA also offers fine capacity tuning in 50G increments to respond to various customer requirements.
Flexible coded modulation is the newly-developed coding scheme to efficiently implement advanced constellation shaping, forward error correction (FEC), and high-order modulation format with high performance and low power. This enables ExaSPEED GAIA to support thousands of operational modes that cover a multitude of customer's transmission links with high energy efficiency. To enhance the performance, ExaSPEED GAIA employs a number of novel compensation algorithms including nonlinear distortion compensation, adaptive fast state of polarization (SOP) tracking, fast device and transmission characteristics estimation, and ultra-long CD compensation for high-baud rate systems*. The performance of ExaSPEED GAIA can be further optimized by combining it with NTT Electronics’ industry-leading high speed coherent driver module (UHB-CDM).
"We are very impressed with the performance of NTT Electronics’ latest ExaSPEED GAIA DSP," commented Hideki Matsui, Vice Head of Photonics System Business Unit, Fujitsu Limited. “This revolutionary DSP makes our products more competitive in the market and enables us to offer innovative solutions. It opens up a new 'terabit era,' which will be a game changer in our industry,” he added.
“This state-of-the-art DSP, we believe would be key to realize the future information-centric society,” said Akio Goto, General Manager of Photonics Device Development Division, NEC Corporation. He also said, “We are excited to introduce ExaSPEED GAIA in conjunction with CDM in our DWDM products to build diverse, high-throughput and green optical networks.”
* https://group.ntt/en/newsrelease/2022/09/05/220905a.html
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230306005007/en/
Contact information
NTT Electronics Contact :
Atul Srivastava, CEO & CTO
NTT Electronics America, Inc.
Tel : +1-201-556-1770
Email : pr@nel-america.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom